推荐同事 机构合作 中文 繁體中文 English 한국어 日本語 Português Español

美国ACCDON公司旗下品牌

021-33361733,021-34243363

chinasupport@letpub.com

登录 注册 新注册优惠

MOLECULAR CANCER THERAPEUTICS 期刊收藏夹

2026年6月最新影响因子数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎点击此处反馈给我们。

期刊名:   ISSN:   研究方向:   IF范围: -   SCI收录:
大类学科:   小类学科:   新锐期刊分区表:   是否OA期刊:   结果排序:
  体验更多LetPub AI科研工具 >>
智能期刊推荐助手

推荐偏好:

 
AI写作痕迹消减工具

 

近期推荐:
全流程投稿协助套餐服务
SCI论文AI润色+人工QC服务
Springer Nature特刊征稿
已发表SCI?是时候来Springer出书了!

按研究方向查看:


MOLECULAR CANCER THERAPEUTICS期刊基本信息Hello,您是该期刊的第99705位访客


基本信息 登录收藏
期刊名字MOLECULAR CANCER THERAPEUTICSMOLECULAR CANCER THERAPEUTICS

MOL CANCER THER
(此期刊被最新的JCR期刊SCIE收录)

LetPub评分
7.7
54人评分
我要评分

声誉
8.6

影响力
6.6

速度
9.3

期刊ISSN1535-7163
安装APP,查看期刊最新消息
iOS版下载安装安卓版下载安装
E-ISSN1538-8514
2025-2026最新IF
(数据来源于网友提供)
注册登录后,查看IF
实时影响因子 截止2026年5月06日:6.4
2025-2026自引率1.4%点击查看自引率趋势图
五年IF
(数据来源于网友提供)
6.395数据由网友[泽雪澜]收集提供
h-index 157
CiteScore
2026年6月最新版
CiteScoreSJRSNIPCiteScore排名
9.502.3921.097
学科分区排名百分位
大类:Medicine
小类:Oncology
Q159 / 428
大类:Medicine
小类:Cancer Research
Q155 / 233

期刊简介
Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.
期刊官方网站http://mct.aacrjournals.org/
期刊投稿格式模板
VIP专享
Word版格式模板  
此模板由LetPub整理,仅供参考。开通VIP可免费下载,并享1w+期刊模板资源。
 
期刊投稿网址http://mct.msubmit.net/cgi-bin/main.plex
该期刊中国学者近期发文 - NewThe Role of Siglec-15 in Tumor Immunity: Mechanisms and Therapy
Author: Li, Lin; Wang, Li; Liu, Qin; Ye, Yingchun; Lei, Qian; Li, Chengwen; Guo, Xiyuan; Nian, Siji; Yuan, Qing
Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 717-726. DOI: 10.1158/1535-7163.MCT-25-0323


IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer
Author: Leslie, Amy R.; Ning, Shu; Sharifi, Masuda; Schaaf, Zachary A.; Maine, James P.; Lou, Wei; Leslie, Kristina D.; Liu, Chengfei; Xu, Hongyu; Lombard, Alan P.; Chen, Hong-Wu; Parikh, Mamta; Dall'Era, Marc; Gao, Allen C
Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 786-798. DOI: 10.1158/1535-7163.MCT-25-0644


Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity
Author: Du, Sicheng; Zhang, Ying; Hao, Ruidong; Qiu, Lupeng; Li, Chao; Li, Yuting; Liu, Rong-Rui; Zhao, Chuan-Hua; Li, Juan; Ye, Sisi; Zhou, Jun; Li, Yantao; Yi, Qiaoyong; Zhang, Shuangshuang; Sun, Minmin; Luo, Tianhang; Xu, Jianming
Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 701-716. DOI: 10.1158/1535-7163.MCT-25-0171


MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma
Author: Bi, Bin; Tang, Liqin; Liang, Ranxi; Wu, Haijing; Huang, Qilan; Pan, Li
Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 771-785. DOI: 10.1158/1535-7163.MCT-25-0564


期刊语言要求经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足MOLECULAR CANCER THERAPEUTICS的语言要求,还能让MOLECULAR CANCER THERAPEUTICS编辑和审稿人得到更好的审稿体验,让稿件最大限度地被MOLECULAR CANCER THERAPEUTICS编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢(1篇)
提交文稿
是否OA开放访问No
通讯方式AMER ASSOC CANCER RESEARCH, 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, USA, PA, 19106-4404
出版商American Association for Cancer Research Inc.
涉及的研究方向医学-肿瘤学
出版国家或地区UNITED STATES
出版语言English
出版周期Monthly
出版年份2001
年文章数 154点击查看年文章数趋势图
Gold OA文章占比36.23%
研究类文章占比:
文章 ÷(文章 + 综述)
91.56%
期刊分区表预警名单 2026年03月发布的新锐学术版:不在预警名单中

2025年03月发布的2025版:不在预警名单中

2024年02月发布的2024版:不在预警名单中

2023年01月发布的2023版:不在预警名单中

2021年12月发布的2021版:不在预警名单中

2020年12月发布的2020版:不在预警名单中
《新锐期刊分区表》
2026年3月发布
点击查看期刊分区表趋势图
大类学科小类学科Top期刊综述期刊
医学 1区2区3区
ONCOLOGY
肿瘤学
2区4区2区
N/A
期刊分区表
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学 3区2区1区
ONCOLOGY
肿瘤学
2区3区2区
期刊分区表
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学 4区2区1区
ONCOLOGY
肿瘤学
2区2区2区
SCI期刊收录coverage Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE)
Scopus (CiteScore)
PubMed Central (PMC)链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1535-7163%5BISSN%5D
平均审稿速度网友分享经验:
平均3月
平均录用比例网友分享经验:
约50%
LetPub助力发表经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色同行资深专家修改润色SCI论文专业翻译SCI论文格式排版专业学术制图等)后论文在MOLECULAR CANCER THERAPEUTICS顺利发表。
快看看作者怎么说吧:服务好评 论文致谢(1篇)
提交文稿
期刊常用信息链接
同领域相关期刊 MOLECULAR CANCER THERAPEUTICS期刊近年CiteScore指标趋势图
该杂志的自引率趋势图 MOLECULAR CANCER THERAPEUTICS期刊分区表趋势图
该杂志的年文章数趋势图 同领域作者分享投稿经验
MOLECULAR CANCER THERAPEUTICS上中国学者近期发表的论文  
  • 同领域相关期刊
  • 期刊CiteScore趋势图
  • 期刊自引率趋势图
  • 期刊分区表趋势图
  • 年文章数趋势图
  • 该期刊中国学者近期发文
  • 期刊分区表相关期刊
  • 同类著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144649.80
    Nature Reviews Clinical Oncology127126.60
    ANNALS OF ONCOLOGY21069.60
    NATURE REVIEWS CANCER39696.20
    CANCER CELL29575.40
    JOURNAL OF CLINICAL ONCOLOGY49414.20
    LANCET ONCOLOGY27442.00
    CANCER RESEARCH41117.00
    SEMINARS IN CANCER BIOLOGY13442.00
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH6722.30
    期刊分区表同大类学科的热搜期刊 浏览次数
    MEDICINE897675
    JOURNAL OF ETHNOPHARMACOLOGY802490
    Frontiers in Immunology745493
    BIOMEDICINE & PHARMACOTHERAPY725387
    BIOMATERIALS715102
    Frontiers in Pharmacology714285
    PHYTOMEDICINE642903
    Frontiers in Oncology618831
    Biomedical Signal Processing and Control599456
    IEEE Journal of Biomedical and Health Informatics596480
  •  

    MOLECULAR CANCER THERAPEUTICS MOLECULAR CANCER THERAPEUTICS
    我来预测明年:
    稳步上升 表现平稳 逐渐下降  刷新
  •  

     
  •  

     
  •  

     
  • 中国学者近期发表的论文
    1.The Role of Siglec-15 in Tumor Immunity: Mechanisms and Therapy

    Author: Li, Lin; Wang, Li; Liu, Qin; Ye, Yingchun; Lei, Qian; Li, Chengwen; Guo, Xiyuan; Nian, Siji; Yuan, Qing
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 717-726. DOI: 10.1158/1535-7163.MCT-25-0323
        PubMed      DOI
    2.IGFBP3-SphK1/S1P Signaling Axis Drives Enzalutamide Resistance in Advanced Prostate Cancer

    Author: Leslie, Amy R.; Ning, Shu; Sharifi, Masuda; Schaaf, Zachary A.; Maine, James P.; Lou, Wei; Leslie, Kristina D.; Liu, Chengfei; Xu, Hongyu; Lombard, Alan P.; Chen, Hong-Wu; Parikh, Mamta; Dall'Era, Marc; Gao, Allen C
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 786-798. DOI: 10.1158/1535-7163.MCT-25-0644
        PubMed      DOI
    3.Preclinical Development and a Case Report of a Nanobody-Based CLDN18.2 CAR-T IMC002 with Reduced On-Target Off-Tumor Toxicity

    Author: Du, Sicheng; Zhang, Ying; Hao, Ruidong; Qiu, Lupeng; Li, Chao; Li, Yuting; Liu, Rong-Rui; Zhao, Chuan-Hua; Li, Juan; Ye, Sisi; Zhou, Jun; Li, Yantao; Yi, Qiaoyong; Zhang, Shuangshuang; Sun, Minmin; Luo, Tianhang; Xu, Jianming
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 701-716. DOI: 10.1158/1535-7163.MCT-25-0171
        PubMed      DOI
    4.MCT8 Modulates Metabolite Uptake and T-cell Exhaustion to Promote Immunosuppression and Tumor Progression in Hepatocellular Carcinoma

    Author: Bi, Bin; Tang, Liqin; Liang, Ranxi; Wu, Haijing; Huang, Qilan; Pan, Li
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 5, pp. 771-785. DOI: 10.1158/1535-7163.MCT-25-0564
        DOI
    5.HRA00129-C004, a Novel c-Met Antibody-Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles

    Author: Tian, Yunan; Zhang, Jieqiong; Sun, Xing; Yang, Changyong; Liao, Cheng
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 3, pp. 371-385. DOI: 10.1158/1535-7163.MCT-24-0680
        PubMed      DOI
    6.Dual Inhibitors of KRASG12D and HSP90 Are Effective against KRASG12D Inhibitor Resistance

    Author: Pulido, Ines; Gunder, Laura C.; Ying, Chenghao; Wang, Yaya; Dai, Yan; Yang, Zimo; Rahnama, Alireza; Li, Jinhua; Sun, Yuetong; Liu, Chuhe; Zhou, Haoxin; Wang, Guoqiang; Foley, Kevin P.; Abdelhady, Khaled; Massad, Malek G.; Prince, Thomas L.; Papautsky, Ian; Ying, Weiwen; Shimamura, Takeshi
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 207-215. DOI: 10.1158/1535-7163.MCT-24-1173
        PubMed      DOI
    7.SDP-LIV1, a Novel and Optimized LIV-1 Antibody-Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors

    Author: Peng, Yani; Yang, Changyong; Dong, Liwei; Sun, Xing; Zheng, Wei; Gong, Yanling; Shi, Qing; Ji, Ping; Chen, Simeng; Zhang, Wei; Liao, Cheng
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 322-332. DOI: 10.1158/1535-7163.MCT-24-0752
        PubMed      DOI
    8.Intratumoral Administration of Engineered circRNAs Encoding Cytosine Deaminase-Uracil Phosphoribosyltransferase and IL-15 Elicits Superior Antitumor Efficacy

    Author: Niu, Dun; Zhang, Shaotong; Ma, Xiaozhuang; Wu, Yaran; Zhu, Junshi; Ran, Jianglang; Shan, Meihua; Dai, Xufang; Lu, Lu; Yang, Mingzhen; Lian, Jiqin
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 2, pp. 272-282. DOI: 10.1158/1535-7163.MCT-25-0356
        PubMed      DOI
    9.A Novel Anti-CD47 Antibody TJH2201: Efficacious Tumor Suppression with Reduced RBC Toxicity via a SIRPα-Independent Mechanism

    Author: Zhang, Huan; He, Fufan; Cao, Lei; Ni, Haiqing; Li, Ninghuan; Liu, Yang; Wu, Min; Liu, Ya; Wu, Bing; Li, Li; Wu, Zhihai; Ling, Xiaomin; Zhou, Shuaixiang; Li, Yiming; Deng, Shuxuan; Wu, Weiwei; Chu, Qian
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 21-33. DOI: 10.1158/1535-7163.MCT-25-0425
        PubMed      DOI
    10.Targeting the ERα DBD-LBD Interface with Mitoxantrone Disrupts Receptor Function through Proteasomal Degradation

    Author: Wang, Han; Luo, Yuxuan; Artham, Sandeep; Wang, Qianqian; Peng, Yi; Yun, Zixi; Li, Xinyue; Wu, Chen; Liu, Zhenghao; Weber-Bonk, Kristen L.; Pai, Chun-Peng; Cao, Yuan; Yue, Jiangan; Park, Sunghee; Keri, Ruth A.; Geng, Lisheng; Mcdonnell, Donald P.; Kao, Hung-Ying; Yang, Sichun
    Journal: MOLECULAR CANCER THERAPEUTICS. 2026; Vol. 25, Issue 1, pp. 107-124. DOI: 10.1158/1535-7163.MCT-25-0405
        PubMed      DOI
  • 同大类学科的其他著名期刊名称 h-index CiteScore
    CA-A CANCER JOURNAL FOR CLINICIANS144649.80
    LANCET70092.40
    MMWR Surveillance Summaries093.20
    Nature Reviews Clinical Oncology127126.60
    NATURE REVIEWS DRUG DISCOVERY289159.20
    NEW ENGLAND JOURNAL OF MEDICINE93374.80
    Signal Transduction and Targeted Therapy081.60
    ANNALS OF ONCOLOGY21069.60
    Nature Reviews Disease Primers4871.30
    World Psychiatry6184.80
    同分区等级的其他期刊名称 h-index CiteScore
    MMWR Surveillance Summaries093.20
    Journal of the National Cancer Center031.20
    Carbon Neutralization018.20
    Journal of Nanostructure in Chemistry027.90
    Journal of the National Comprehensive Cancer Network8819.40
    Journal of Advanced Research3621.70
    Soft Science014.30
    NEW ASTRONOMY REVIEWS5236.80
    Wiley Interdisciplinary Reviews-Data Mining and Knowledge Discovery3126.60
    ACS Measurement Science Au014.60
以上SCI期刊相关数据和信息来源于网络,仅供参考。
投稿状态统计: 我要评分:
投稿前担心稿件结构或语言不够规范?试试稿件自查工具,一键检测 >>
与期刊沟通模版下载中心
VIP专享
掌握投稿全流程专业邮件模板,让您的学术沟通高效得体,显著提升论文发表效率!开通VIP可免费下载。
投稿信 (Cover Letter) 模板 回复信 (Response Letter) 模板 投稿状态查询 (Inquiry Letter) 模板
返修延期交稿 (Requesting Extension) 模板 变更作者信息申请 (Author Changes) 模板 拒稿后申诉信 (Appeal Letter) 模板
撤稿申请 (Withdrawal Request Letter) 模板 更正/勘误说明 (Corrigendum/Erratum) 模板 投稿前咨询信 (Pre-submission Inquiry) 模板
没有机构邮箱的说明 (Lack of institutional Email) 模板 更新中...

同领域作者分享投稿经验:共73


    联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们

    © 2010-2026 中国: LetPub上海    网站备案号:沪ICP备10217908号-1    沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)

    增值电信业务经营许可证:沪B2-20211595    网络文化经营许可证:沪网文[2023]2004-152号

    礼翰商务信息咨询(上海)有限公司      办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室